Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 27, 2022

SELL
$0.18 - $3.51 $1,101 - $21,474
-6,118 Reduced 1.7%
352,800 $59,000
Q2 2022

Aug 08, 2022

BUY
$2.79 - $4.45 $1 Million - $1.6 Million
358,713 Added 174981.95%
358,918 $1.1 Million
Q1 2022

May 04, 2022

BUY
$2.26 - $3.84 $463 - $787
205 New
205 $1,000

Others Institutions Holding CFRX

About CONTRAFECT Corp


  • Ticker CFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,332,700
  • Market Cap $1.18M
  • Description
  • ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...
More about CFRX
Track This Portfolio

Track Prospera Financial Services Inc Portfolio

Follow Prospera Financial Services Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prospera Financial Services Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prospera Financial Services Inc with notifications on news.